UK Panel Rejects Nationwide Prostate Cancer Screening, Endorses Targeted Testing for BRCA-Linked Risk
Advisers warn mass PSA screening would cause more harm than benefit, prompting a narrow proposal focused on men with BRCA gene mutations
A leading government advisory panel has concluded that the United Kingdom should not introduce routine prostate cancer screening for the general male population, arguing that existing evidence shows it would offer only marginal reductions in mortality while causing significant levels of overdiagnosis and overtreatment.
Instead, the UK National Screening Committee has put forward a targeted proposal recommending biennial testing only for men with confirmed BRCA1 or BRCA2 gene mutations, beginning at age forty-five and ending at sixty-one.
The draft recommendation follows a major review of available research on population-level screening using the prostate-specific antigen test.
The panel found that such screening would likely detect large numbers of slow-growing cancers that would never pose a threat during a man's lifetime.
Treating these cases, it warned, could lead to avoidable anxiety and life-altering side-effects such as incontinence and erectile dysfunction.
The committee also considered whether screening should be offered to Black men, who face substantially higher prostate-cancer risks, or men with a family history of the disease.
It ultimately concluded that current evidence for these groups remains too limited and uncertain to justify a screening programme.
Modelling suggested that annual tests for Black men could result in overdiagnosis rates nearing half of all cancers detected.
The recommendation has prompted contrasting responses.
Cancer Research UK and the Royal College of General Practitioners have supported the cautious, evidence-based approach, noting the PSA test’s longstanding limitations.
However, several charities and public figures expressed disappointment, arguing that the decision overlooks high-risk groups and could lead to more late-stage diagnoses.
Advocates point to newer diagnostic techniques, such as MRI-guided assessments, that they say may reduce the risks associated with traditional screening.
Health Secretary Wes Streeting said he would review all arguments before issuing a final ruling, emphasising his goal of faster diagnosis and improved outcomes across the NHS.
The proposal is now open to a twelve-week public consultation, with the government expected to make its final decision in March.
Should the recommendation proceed, only a few thousand BRCA-positive men nationwide would be eligible for regular screening under the new programme.
Instead, the UK National Screening Committee has put forward a targeted proposal recommending biennial testing only for men with confirmed BRCA1 or BRCA2 gene mutations, beginning at age forty-five and ending at sixty-one.
The draft recommendation follows a major review of available research on population-level screening using the prostate-specific antigen test.
The panel found that such screening would likely detect large numbers of slow-growing cancers that would never pose a threat during a man's lifetime.
Treating these cases, it warned, could lead to avoidable anxiety and life-altering side-effects such as incontinence and erectile dysfunction.
The committee also considered whether screening should be offered to Black men, who face substantially higher prostate-cancer risks, or men with a family history of the disease.
It ultimately concluded that current evidence for these groups remains too limited and uncertain to justify a screening programme.
Modelling suggested that annual tests for Black men could result in overdiagnosis rates nearing half of all cancers detected.
The recommendation has prompted contrasting responses.
Cancer Research UK and the Royal College of General Practitioners have supported the cautious, evidence-based approach, noting the PSA test’s longstanding limitations.
However, several charities and public figures expressed disappointment, arguing that the decision overlooks high-risk groups and could lead to more late-stage diagnoses.
Advocates point to newer diagnostic techniques, such as MRI-guided assessments, that they say may reduce the risks associated with traditional screening.
Health Secretary Wes Streeting said he would review all arguments before issuing a final ruling, emphasising his goal of faster diagnosis and improved outcomes across the NHS.
The proposal is now open to a twelve-week public consultation, with the government expected to make its final decision in March.
Should the recommendation proceed, only a few thousand BRCA-positive men nationwide would be eligible for regular screening under the new programme.
